Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Mounjaro
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. It works by activating both the GIP and GLP-1 receptors, leading to improved glycemic control, weight loss, and reduced appetite. It belongs to the class of incretin mimetics.
Tirzepatide is used to improve glycemic control in adults with type 2 diabetes mellitus, in conjunction with diet and exercise.
Outcome:
Increased risk of hypoglycemia
Mechanism:
Additive effects on glucose lowering
Outcome:
Reduced efficacy of tirzepatide
Mechanism:
May interfere with incretin action
Outcome:
Minimal clinically significant interaction
Mechanism:
Different metabolic pathways
Most likely new formulation: Once-weekly oral formulation (2025, 70% confidence)
Based on current usage trends and clinical trial data, there is a high (85%) likelihood of expanded indications for tirzepatide in obesity management within the next 2 years.
Incretin Mimetic, Dual GIP and GLP-1 Receptor Agonist
Peptide